Vancomycin-resistant enterococci bacteremia: Risk factors for mortality and influence of antimicrobial therapy on clinical outcome

Journal of Infection

Volumn 58, Issue 3, 2009, Pages 182-190

  Han, Sang Hoon ^a   Chin, Bum Sik ^a   Lee, Han Sung ^a   Jeong, Su Jin ^a   Choi, Hee Kyoung ^a   Kim, Chang Oh ^a   Yong, Dongeun ^a   Choi, Jun Yong ^a   Song, Young Goo ^a   Lee, Kyungwon ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Bacteremia; Mortality; Vancomycin resistant enterococci

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CORTICOSTEROID; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK FACTOR; SEPTIC SHOCK; SURVIVAL RATE; THERAPY DELAY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SHOCK, SEPTIC; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

EID: 61349182487     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.01.013     Document Type: Article

References (27)

1. Uttley A.H., Collins C.H., Naidoo J., and George R.C. Vancomycin-resistant enterococci. Lancet 1 (1988) 57-58
2. Pfaller M.A., Jones R.N., Doern G.V., and Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrobial Agents Chemother 42 (1998) 1762-1770
3. Low D.E., Keller N., Barth A., and Jones R.N. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 32 Suppl. 2 (2001) S133-S145
4. Jones R.N., Marshall S.A., Pfaller M.A., Wilke W.W., Hollis R.J., Erwin M.E., et al. Nosocomial enterococcal blood stream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 29 (1997) 95-102
5. Bhavnani S.M., Drake J.A., Forrest A., Deinhart J.A., Jones R.N., Biedenbach D.J., et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 36 (2000) 145-158
6. DiazGranados C.A., and Jernigan J.A. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 191 (2005) 588-595
7. Erlandson K.M., Sun J., Iwen P.C., and Rupp M.E. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 46 (2008) 30-36
8. Lodise T.P., McKinnon P.S., Tam V.H., and Rybak M.J. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 34 (2002) 922-929
9. Vergis E.N., Hayden M.K., Chow J.W., Snydman D.R., Zervos M.J., Linden P.K., et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 135 (2001) 484-492
10. Ghanem G., Hachem R., Jiang Y., Chemaly R.F., and Raad I. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 28 (2007) 1054-1059
11. DiazGranados C.A., Zimmer S.M., Klein M., and Jernigan J.A. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 41 (2005) 327-333
12. Linden P.K., Pasculle A.W., Manez R., Kramer D.J., Fung J.J., Pinna A.D., et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 22 (1996) 663-670
13. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
14. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
15. Peralta G., Sanchez M.B., Garrido J.C., De Benito I., Cano M.E., Martinez-Martinez L., et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 60 (2007) 855-863
16. Kang C.I., Kim S.H., Kim H.B., Park S.W., Choe Y.J., Oh M.D., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37 (2003) 745-751
17. Domig K.J., Mayer H.K., and Kneifel W. Methods used for the isolation, enumeration, characterisation and identification of Enterococcus spp. 1. Media for isolation and enumeration. Int J Food Microbiol 88 (2003) 147-164
18. Domig K.J., Mayer H.K., and Kneifel W. Methods used for the isolation, enumeration, characterisation and identification of Enterococcus spp. 2. Pheno- and genotypic criteria. Int J Food Microbiol 88 (2003) 165-188
19. CLSI. Performance standards for antimicrobial disk susceptibility testing: 16th informational supplement (2007), Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, USA p. M100-S17
20. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
21. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 13 (1985) 818-829
22. Gyssens I.C. Quality measures of antimicrobial drug use. Int J Antimicrob Agents 17 (2001) 9-19
23. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 31 Suppl. 4 (2000) S131-S138
24. World Health Organization. International statistical classification of diseases and related health problems. 2nd ed. (2004), World Health Organization, Geneva 10th revision
25. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
26. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31 (2003) 1250-1256
27. Garbutt J.M., Ventrapragada M., Littenberg B., and Mundy L.M. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 30 (2000) 466-472